Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TGIC grabbed small starter @ .80
TGIC .97 -52.68%
So far so good
DCTH (2.22) Delcath Adds Atlantic Health to Phase III Trial for Metastatic Melanoma
Thursday, June 19 2008 9:34 AM, EST
Market Wire "US Press Releases "
NEW YORK, NY -- (MARKET WIRE) -- 06/19/08 -- Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the Atlantic Melanoma Center of Atlantic Health has joined Delcath's Phase III clinical trial for the treatment of inoperable metastatic melanoma in the liver using the Company's Percutaneous Hepatic Perfusion (PHP) System for the isolated, high dose delivery of the anti-cancer agent melphalan. Atlantic Health is the fifth center in this multi-center study testing the Delcath System.
Delcath and Atlantic Health have entered into a clinical research agreement to join the National Cancer Institute (NCI) led study. Eric Whitman, MD, FACS, Director, Atlantic Melanoma Center and Medical Director, Office of Grants and Research, will serve as the Principal Investigator of the study. The PHP treatments will be performed at Morristown Memorial Hospital , in Morristown, New Jersey , part of Atlantic Health . Dr. Whitman brings many years of experience in melanoma and clinical research to this trial, and has been at the forefront of initiating new and promising technologies at his institution. On joining this trial, Dr. Whitman said, "I am very pleased to be able to enroll patients in this Phase III trial for metastatic melanoma, a disease for which an effective treatment has eluded us. Delcath's PHP System shows tremendous promise in its application to this indication, and I look forward to offering this new treatment to my patients."
Delcath Systems continues adding cancer centers to this Phase III trial, which has accrued one-third of the required ninety-two patients. On this recent expansion to include Atlantic Health , Richard Taney, President and CEO of Delcath, stated, "The Delcath System is now available at a number of leading cancer centers. Delcath continues working to reach its stated goals of expanding this Phase III trial and increasing physician awareness of the Delcath PHP System in order to improve the availability of this treatment to patients diagnosed with inoperable metastatic melanoma to the liver. We will continue to add centers to this trial, and hope to complete enrollment in 2009."
The Phase III Study
The Phase III study is designed to test Delcath's proprietary PHP System for the regional delivery of melphalan to the liver to treat patients with metastatic ocular and cutaneous melanoma who have unresectable tumors in the liver. The Delcath System is designed to deliver significantly higher doses of anti-cancer drugs to a patient's liver while preventing entry of the drugs to the rest of the patient's circulation. This isolation limits toxicities that result from systemic chemotherapy treatments.
Patients in the Phase III trial initially are randomized into one of two treatment arms, including immediate treatment with melphalan via the Delcath System or treatment with best alternative care. The study is designed to evaluate the duration of tumor response in each of the two study arms. Following guidelines established by U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA), when disease progresses in patients enrolled in the best alternative care arm of the trial, they are permitted to "cross over" and receive treatment with the Delcath System. The Phase III study, which recently exceeded 33% enrollment, is expected to be completed in 2009, leading to an application to the US Food and Drug Administration (FDA) for commercial approval of the PHP System.
About Atlantic Health and Morristown Memorial Hospital
Atlantic Health (atlantichealth.org) is one of the largest non-profit health care systems in New Jersey and includes Overlook Hospital in Summit and Morristown Memorial Hospital . The two hospitals have a combined total of 1,133 licensed beds and more than 2,100 affiliated physicians providing a wide array of health care services to the five million residents of 11 Northern and Central New Jersey counties. Specialty services include cardiovascular care, neurosciences, pediatrics, cancer care, orthopedics, diabetes care, gastroenterology, trauma and emergency medicine, behavioral health, minimally invasive surgery, radiology and advanced diagnostics, women's health and maternal fetal medicine, home and hospice care and rehabilitation services. In 2008, Atlantic Health will complete the new Gagnon Heart Hospital , a 200,000 square-foot facility at Morristown Memorial that will consolidate Atlantic Health's cardiovascular services. The Gagnon Heart Hospital includes services at Morristown Memorial and Overlook hospitals.
Atlantic Health maintains a partnership with The Cancer Institute of New Jersey . Atlantic Health's hospitals are accredited by The Joint Commission . Atlantic Health is the primary academic and clinical affiliate in New Jersey of Mount Sinai School of Medicine and The Mount Sinai Hospital .
About Delcath Systems, Inc.
Delcath Systems is a developmental stage company testing its percutaneous perfusion technology for the isolated delivery of high doses of therapeutic and chemotherapeutic agents. The Delcath System is currently being tested with the drug melphalan in Phase III and Phase II clinical trials. The Company's intellectual property portfolio currently consists of twenty-eight patents on a worldwide basis including the U.S., Europe , Asia and Canada . For more information, please visit the Company's website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission . You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.
Company Contact:
Delcath Systems, Inc.
Richard Taney
(212) 489-2100
www.delcath.com
Media Relations Contact:
The Global Consulting Group
Ivette Almeida
ialmeida@hfgcg.com
Investor Relations Contact:
Strategic Growth International, Inc.
Richard E. Cooper
(212) 838-1444
ITKH (.04) iTeknik Holding Corporation Launches New Proprietary Software
Thursday, June 19 2008 9:35 AM, EST
Market Wire "US Press Releases "
COMMERCE, MI -- (MARKET WIRE) -- 06/19/08 -- iTeknik Holding Corporation (PINKSHEETS: ITKH), a leader in the telecommunications industry with two subsidiary companies, TeleCents Communications and Send Global Corporation , today announced that the Company's new proprietary software application TCI Command is now operational. According to the company, the new System consists of a proprietary software application that was developed in-house by iTeknik personnel. TCI Command will provide a much larger platform to enable iTeknik's subsidiaries to sell more services and airtime.
Additionally, the system saves iTeknik's customers a significant amount of money in two ways: First, airtime that is sold to clients is priced at extremely competitive rates when compared to major domestic and international carriers. Second, the system has a complete back office function already in place for customers. This enables customers to realize significant savings by avoiding programming and up-front expenses. Due to the many benefits provided by the new system, iTeknik's strategy is to gain a significant market share in the Virtual Switch Operator (VSO) business.
"A virtual switch application like TCI Command provides any user full access to all of the benefits of a multimillion dollar switching system and a global carrier network with none of the expense, overhead, or capital investment," said Jeff Lauzon, CEO of TeleCents Communications, Inc. "Customers who provide any type of domestic or international voice services will be able to use our system regardless of how they deliver their products. We are providing them a complete back office to manage their business as well as provide them access to our least cost routing from multiple International carriers. We expect our new TCI Command to be a big hit for our current customers and enable us to bring on many new customers," Lauzon said.
Recently the company also announced that it had purchased new state-of-the-art Cirrus Softswitch System hardware and that it was in the final stages of changing its operations from the legacy system to the new hardware.
About iTeknik Holding Corporation
iTeknik Holding Corporation's (ITKH) strategy is to grow by acquiring companies with unique products, technology and solid growth potential. TeleCents Communications, Inc. (TCC) and Send Global Corporation (www.sendglobal.com) are wholly owned subsidiaries of ITKH. Together they have been offering cutting edge retail and wholesale telecommunications products and services for more than eleven years including International and Domestic gateway services through Tier-1 carriers. Through VoIP, data, and traditional communications platforms, iTeknik provides custom calling solutions and a proprietary ANI gateway solution. Send Global provides high quality, value priced international calls from the convenience of a mobile phone. For more information please visit our website www.iteknik.com.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.
Contact:
Andrew Barwicki
Investor Relations
516-662-9461
http://www.iTeknik.com
MVTG (.205) Mantra Venture Group Announces Creation of Mantra China Limited
Thursday, June 19 2008 9:30 AM, EST
PR Newswire "US Press Releases "
SEATTLE , June 19 /PRNewswire-FirstCall/ - Mantra Venture Group Ltd. ("Mantra" - OTCBB: MVTG - FSE: 5MV) is pleased to announce that it has established Mantra China Limited , a Hong Kong company, to develop and market Mantra's technologies and services throughout Asia. Mantra China is a joint venture between Mantra and two Hong Kong based partners, Green China Developments Limited and Gateview Group Limited . Mantra holds a 51% stake in the new venture.
"Mantra China will be the vehicle for the Mantra group of companies to establish a strong brand presence in Asia, identify new markets for our products, and build strategic alliances with technology developers, manufacturers and financiers", says Dan Funaro, member of Mantra's Corporate Advisory Board. Mr. Funaro goes on to say, "the new venture also aims to establish Mantra as a North American distributor of innovative green technologies developed and produced in Asia."
Mantra China is already in negotiations to acquire exclusive North American distribution rights to a line of solar power LED products produced in China . "There are an abundance of opportunities available here in North America to market and distribute these innovative products", says Larry Kristof, President and C.E.O. of Mantra, "we have identified many sectors such as government, business and individual consumers who will benefit tremendously from the use of these products, both in terms of cost-savings and also in terms of reducing their carbon footprint."
About Mantra:
Mantra, through its group of sustainable energy, carbon reduction and consumer product subsidiaries, is active in the green technology marketplace with an innovative, multi-faceted approach focused on profitability through sustainability. By aggressively seeking out new technologies and innovating solutions for a cleaner earth for everyone, Mantra intends to provide a highly profitable, socially and environmentally responsible investment for its shareholders.
Mantra is a public company quoted on the OTC BB under the symbol MVTG and on the Frankfurt Stock Exchange under the symbol 5MV. For more information please visit us at www.mantraenergy.com.
Forward-Looking Statements:
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See Mantra Venture Group's filings with the Securities and Exchange Commission which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
CONTACT: Terry Johnston, Investor Relations, Phone: (604) 267-3022, Email: tjohnston@mantraenergy.com, Website: http://www.mantraenergy.com
SOURCE Mantra Venture Group Ltd.
LEVP (1.84) Lev Pharmaceuticals to Present at the Jefferies & Co. 2nd Annual Healthcare Conference
Thursday, June 19 2008 9:32 AM, EST
Business Wire "US Press Releases "
NEW YORK --(BUSINESS WIRE)--
Lev Pharmaceuticals, Inc. ("Lev" or the "Company") (OTCBB:LEVP) announced today that Joshua Schein, Ph.D., chief executive officer of Lev will present at the Jefferies & Co. 2nd Annual Healthcare Conference, being held June 24-26 in New York City, NY . Dr. Schein will present a corporate progress report, including an update on the Company's lead product candidate, Cinryze(TM) (C1 inhibitor (human)). The Lev presentation is scheduled to begin at 1:30 p.m. Eastern Standard Time on Thursday, June 26th .
The Lev presentation will be webcast live and may be accessed by visiting the Investor Relations section of the Company's website at www.levpharma.com. The 15-minute presentation will also be available on the Lev website in replay format for a limited time following the conference.
About Lev Pharmaceuticals, Inc.
Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev's lead product candidate, Cinryze(TM) (C1 inhibitor (human)), is being developed as a replacement therapy for hereditary angioedema (HAE), also known as C1 inhibitor deficiency. Cinryze(TM) has been granted orphan drug status for the acute and prophylactic treatment of HAE, potentially securing, upon approval, market exclusivity for seven years. Additionally, Lev is in the process of prioritizing its C1 inhibitor development platform for the treatment of selective other diseases and disorders in which inflammation is known or believed to play an underlying role.
For more information about Lev, C1 inhibitor, or HAE, please contact Lev directly at 212-682-3096, or visit Lev's website at www.levpharma.com.
Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our plans and objectives of management are forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including risks related to new information arising out of clinical trial results, the risk that the safety and/or efficacy results of existing clinical trials for Cinryze(TM) will not support approval for a biologics license, the risk that FDA may require us to conduct additional clinical trials for Cinryze(TM), the risk that FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that FDA will not approve a product for which a biologics license has been applied, our heavy dependence on the success of Cinryze(TM), our dependence on our suppliers, our dependence on third parties to manufacture Cinryze(TM), obtaining regulatory approval to market Cinryze(TM), market acceptance of Cinryze(TM), maintaining the orphan drug status associated with Cinryze(TM), the risks associated with dependence upon key personnel, and our ability to obtain additional funding to support our business activities. These and other risks are described in greater detail in the "Risk Factors that May Affect Results" section of our filings with the SEC. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. We do not assume any obligation to update any forward-looking statements.
Source: Lev Pharmaceuticals, Inc.
EMHD (.16) EMTA Holdings, Inc. Will Hold Live Conference Call for Shareholders
Thursday, June 19 2008 9:30 AM, EST
PR Newswire "US Press Releases "
SCOTTSDALE, Ariz ., June 19 /PRNewswire-FirstCall/ -- EMTA Holdings, Inc. , (OTC Bulletin Board: EMHD), maker of XenTx(TM), Synergyn(TM) and other engine treatment and fuel efficiency products, today announced that they will conduct a live conference call with shareholders and other interested parties.
EMTA Holdings, Inc. in their ongoing interest in keeping shareholders and investors up to date on the success of the company over the past several months as well as addressing the general concerns over the fluctuating stock price will give shareholders and any other interested parties an opportunity to talk directly with the President/CEO, Edmond L. Lonergan. The conference call will take place this Friday, June 20, 2008 at noon ( 12:00 pm) EDT .
Anyone wishing to participate in this call should dial in by calling (641) 715-3300. The participant code is 471878#. In order to facilitate a productive and informative dialog please provide Mr. Lonergan with your questions prior to the call. Send all questions/comments to elonergan@emtacorp.com.
"I welcome the opportunity to answer questions and hear from our shareholders and investors. I believe that open and honest dialog is essential and I look forward to our conference call," said Ed Lonergan.
About EMTA Holdings
EMTA Holdings, Inc. , develops and manufactures innovative products to conserve energy, particularly for petroleum-based fuels. The Company's engine and fuel additives are marketed under the brands XenTx(TM), Synergyn(TM), and CleanBoost(TM) brands, and are sold both to commercial and retail customers. They are available from key distributors, major automotive retailers and online at http://www.emtacorp.com/store. For additional information on EMTA products, please visit http://www.xentx.com.
Forward-Looking Statements: This press release discusses certain matters that may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the intent, belief or current expectations of EMTA Corp. ("the Company") and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results such as, but not limited to: the ability of the Company to raise necessary capital; to attract and retain effective management; the lack of viable commercial applications or the failure of third-party contractors to perform their contractual obligations. Prospective investors are also referred to the other risks identified from time to time in the Company's reports and registration statement filed with the Securities and Exchange Commission .
CONTACT:
Larry Downs
Director of Communications
Equiti-trend Advisors
800-585-6988
lwdowns@equititrend.com
Or
Paula C. Wright
VP IR/PR/Media
EMTA Holdings, Inc.
480-607-0251
pwright@corporatearchitects.com
SOURCE EMTA Holdings, Inc.
GNBT (.9799) Generex Biotechnology Presented Data At The Endocrine Society's Annual Meeting
Thursday, June 19 2008 9:30 AM, EST
PrimeNewswire "PrimeNewswire "
WORCESTER, Mass ., June 19, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, made a podium presentation of data from a company-sponsored study at The Endocrine Society's 90th Annual Meeting (ENDO, www.endo-society.org) in San Francisco on June 18, 2008 .
Doctor Jaime Guevara-Aguirre of the Institute of Endocrinology IEMYR , Quito, Ecuador , made a podium presentation of an abstract entitled, "Human Insulin Therapy is Safe, Efficacious, and Less Costly Than Insulin Analogs in the Treatment of Type-1 Diabetes." The abstract was co-authored by Doctor Jaime Guevara-Aguirre and Doctor Marco Guevara-Aguirre, both of the Institute of Endocrinology IEMYR ; Professor Arlan L. Rosenbloom of the University of Florida ; and Dr. Gerald Bernstein, the company's Vice-President for Medical Affairs.
The one-year study compared the efficacy and safety of analog versus human insulins. The study showed that human insulin administered as basal injection and with meals as orally absorbed regular insulin (Generex Oral-lyn(tm), the company's proprietary oral insulin spray product) attained lower pre-meal glucose, HbA1c, and fructosamine concentrations when compared with a regimen using basal and pre-prandial insulin analogs in Type-1 diabetes. The cost of insulin analogs, basal and pre-prandial, is greater than that of recombinant human insulin, but this greater expense has been considered justified by therapeutic advantages. The study concluded that human insulin, when delivered through the buccal mucosa, is not inferior to analogues in the long-term treatment of Type-1 diabetes and could be used as a less costly alternative.
The company also made a poster presentation of an abstract entitled, "Serum Fructosamine Measurement is Adequate for Monitoring Long-Term Metabolic Control in Type-1 Diabetes." The abstract was co-authored by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR , Quito, Ecuador ; Edward Vidgen of the University of Toronto ; Professor Arlan L. Rosenbloom of the University of Florida ; and Dr. Gerald Bernstein, the company's Vice-President for Medical Affairs.
About The Endocrine Society
ENDO's mission is to advance excellence in endocrinology and promote its essential role as an integrative force in scientific research and medical practice. ENDO is an international body with thirteen thousand members from over eighty-five countries. The diverse membership represents medicine, molecular and cellular biology, biochemistry, physiology, genetics, immunology, education, industry, and allied health. Society members represent the full range of disciplines associated with endocrinologists: clinicians, researchers, educators, fellows and students, industry professionals, and health professionals who are involved in the field of endocrinology. These professionals are dedicated to the research and treatment of the full range of endocrine disorders: diabetes, reproduction, infertility, osteoporosis, thyroid disease, obesity/lipids, growth hormone, pituitary tumors, and adrenal insufficiency. ENDO works to foster a greater understanding of endocrinology amongst the general public and practitioners of complementary medical disciplines and to promote the interests of all endocrinologists at the national scientific research and health policy levels of government.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and which was approved for sale in India in October 2007 , is in Phase 3 clinical trials at several sites around the world. For more information, visit the Generex website at www.generex.com.
The Generex Biotechnology Corp. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3831
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission , which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
CONTACT: CEOcast, Inc.
For Generex:
Gary Nash
212-732-4300
American Capital Ventures, Inc.
Howard Gostfrand
305-918-7000
RPDM gapping a bit. Will it hold its gains and reverse?
RPDM worst ever lol
WRGL .011 -96.33% for all the gamblers out there
Yea
Well for the past few sessions it was NITE. Now looking like VERT is running the show
I would hope so but it's still so scary. I grabbed some @ .01 for the heck of it but I'm not too sure of it
Agreed. They just dont give it a chance to bounce
CSLI (.08) Critical Solutions and Robinson Aviation Attend the 80th Annual AAAE Conference and Exposition
Wednesday, June 18 2008 12:58 PM, EST
PrimeNewswire "PrimeNewswire "
CLEVELAND , June 18, 2008 (PRIME NEWSWIRE) -- Critical Solutions Inc. (Pink Sheets:CSLI) , through its wholly-owned subsidiary, Critical Power Solutions International, Inc. and its partner, Robinson Aviation, attended the 80th Annual American Association of Airport Executives (AAAE) Conference and Exposition on June 8-11, 2008 . Management discussed using the Company's mobile towers equipped with solar and wind generated power, for the deployment of wirelessly networked perimeter security solutions with the nation's top airport managers and executives.
" Robinson Aviation (RVA), Inc. is a worldwide leader in airport security studies training and is in constant search for new products and new applications to support Homeland Security," said Mike Lee, Founder and CTO of Critical Power Solutions International, Inc. "Airports, due to their extensive perimeters, are a natural market for our alternative powered systems whether for security, communication, or asset management. In a world of heightened security, this type of technology provides a wealth of benefits to airport personnel. Live video from multiple locations reduces the need for field security personnel. Analytic analysis of video streams means fewer video operators are required and the cost/benefit ratio of our mobile deployment versus trenching installation means more cameras can be put into service."
The AAAE provided an excellent opportunity for Critical Solutions to create additional awareness for their perimeter security solutions. Working with the professionals of Robinson Aviation at the AAAE's Annual Conference allowed the Company to broaden its exposure to airport managers and security chiefs from around the nation. The 80th Annual show drew close to 2,000 delegates for a program that included discussions on the impact of high fuel prices on air service; roundtables by FAA and TSA officials; presentations on general aviation airport security; and panel discussions on numerous technical and marketing topics affecting commercial service and GA airports.
About Robinson Aviation
RVA provides air traffic control and engineering services to Government and industry. RVA through its subsidiary Sentinel Security Warehouse, Inc. identifies new security products, technologies and services for use by government, military, and civilian organizations. RVA has taken part in many significant projects both as a prime and a subcontractor. RVA's area of concentration include: providing air traffic control services; radar systems engineering; airport traffic control tower design and communications equipment installation and maintenance; and airport security assessment, planning, and training.
About Critical Solutions Inc.
Critical Solutions Inc. , through its wholly owned subsidiary, Critical Power Solutions International, Inc. , manufactures and sells a line of patent pending self-powered trailer systems that can be rapidly deployed to power physical security and communication requirements for areas where power is difficult to obtain, or where conventional power means are too expensive to deploy. The company utilizes non-traditional power sources such as solar, wind, and hydrogen to provide efficient recovery, backup and primary power systems. The company's alternative energy trailer systems have been chosen by a FORTUNE 500 defense contractor to secure nuclear power plants, by the Federal Bureau of Prisons for Emergency Response Teams, and to the Marines for emergency communications.
The Critical Solutions Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4852
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic and business conditions, and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
CONTACT: ZA Consulting Inc.
Investor Contact
(212) 505-5976
pressreleases@za-consulting.net
AWYI (.0038) Ariel Way's CEO Arne Dunhem is featured in an interview on CEONEWS.Tv
Wednesday, June 18 2008 12:51 PM, EST
M2 "Press Wire "
M2 PressWIRE - June 18, 2008 - "Stocks that take off like Rockets!" today is: Ariel Way, Inc. (OTCBB:AWYI) Join us at www.Rocket-Stocks.com for the most exciting online financial information concerning OTCBB, Pinksheet, NASDAQ and TSX companies on the market. To have your site profiled on our extensive network, call: 202.558.7500 or contact info@rocket-stocks.com ___________________________________________________________________________________________________________________________
Ariel Way, Inc. (OTCBB:AWYI) www.Rocket-Stocks.com 6/18/08 Arne Dunhem , CEO of Ariel Way, Inc. is featured in an interview on CEONEWS.Tv . Mr Dunhem discusses the company's most recent press release, and its impact on future growth.
The interview can be accessed at http://www.ceonews.tv .
About CEONEWS.Tv:
CEONEWS.Tv is an online, market news provider that brings investors current news about the market of companies from the Pinksheets, Bulletin Boards, NASDAQ, AMEX, NYSE and TSX. CEONEWS.Tv offers one-on-one interviews with the CEO's, CFO's, COO's and Presidents of companies to deliver answers to the questions that investors would like asked. Through these interviews Executives share their insights, accomplishments, current projects, daily challenges they face and future goals and aspirations they have for the companies that they lead. For further information please visit http://www.ceonews.tv. Call 202-558-7500 or email interviews@ceonews.tv
About Ariel Way, Inc.
Ariel Way, Inc. , a Florida corporation ("Ariel Way" or the "Company"), is a technology and services company for highly secure global communications, multimedia and digital signage solutions and technologies. The Company is focused on developing innovative and secure technologies, acquiring and growing profitable advanced technology companies and global communications service providers and creating strategic alliances with companies in complementary product lines and service industries. More information about Ariel Way can be found on the web at http://www.arielway.com.
Join us at www.Rocket-Stocks.com for the most exciting online financial information concerning OTCBB, Pinksheet, NASDAQ and TSX companies on the market. To have your site profiled on our network, call: 202.558.7500 or contact info@rocket-stocks.com ___________________________________________________________________________________________
About Rocket-Stocks.com
Rocket-Stocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies. The Rocket-Stocks email stock report service is free to those investors who visit our website. The service is designed to notify investors of undervalued and often overlooked stocks. Visitors are introduced to OTCBB, Pinksheet and TSX companies that have the potential of showing increased activity and Running Positively Away from the rest of the market. To see this Free service in action, visit the Bulls On The Run home page at www.Rocket-Stocks.com.
Disclaimer: Verify all claims and do your own due diligence. Rocket-Stocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Rocket-Stocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Rocket-Stocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Rocket-Stocks.com is owned and operated by West-Main Communications . Neither Rocket-Stocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or in part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Rocket-Stocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Rocket-Stocks.com's statements and opinions and such statements and opinions cannot be considered independent. Rocket-Stocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Rocket-Stocks.com's services are often paid for using free-trading shares. Rocket-Stocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.
Join us at www.Rocket-Stocks.com for the most exciting online financial information concerning OTCBB, Pinksheet, NASDAQ and TSX companies on the market. To have your site profiled on our network, call: 202.558.7500 or contact info@rocket-stocks.com
((Comments on this story may be sent to info@m2.com))
© 2008 M2 COMMUNICATIONS LTD
RPDM .01 new lows... I'll stay away
PCTU (.07) Mexico's Secretaria de Hacienda y Credito Publico Validates and Values Four Crystal Funding, Inc. Bonds
Wednesday, June 18 2008 12:00 PM, EST
PR Newswire "US Press Releases "
NEW YORK , June 18 /PRNewswire-FirstCall/ -- Four Crystal Funding, Inc. (OTC: PCTU.PK) announced today that the bonds it has acquired are 1930 Series X Class C $100.00 Pesos gold backed, sovereign, bearer bonds.
The "Titular de la Unidad de Credito Publico" (who in his capacity has the power and authority to make the statements presented herein, declared the following:
-- That the GOLD CERTIFICATES are transferable, valid and an outstanding obligation of the Republic of Mexico .
-- The terms and conditions of the verification and authentication shall be governed and constructed in accordance with the laws of Mexico .
-- Additionally thereto by regulations of the International Chamber of Commerce in Paris Uniform Rules of Collection for Demand guarantees, Publication 458.
-- The total face values of 112 of the Gold Certificates mentioned as actualized at the current value, as of 6/13/2007, are $5,083,884,087.52 .
Four Crystal Funding, Inc. received 89 of the gold backed certificates (as stated above) valued at $4,039,872,177 , as of June 13, 2007 . Since the bonds were originally issued in 1930 it is very difficult for the Company to monetize the actual value of the bonds and therefore they could be significantly discounted when, and if, they are liquidated.
Michael J. Parrella, Chairman and CEO of Four Crystal Funding, Inc. said, "We received substantial validation before entering into this transaction and the above facts are representative of the data we used to confirm the value for our shareholders. We hope this assists investors and our shareholders to understand the true value and validity of the bonds we received."
ABOUT FOUR CRYSTAL FUNDING, INC.
Four Crystal Funding, Inc. is an investment fund founded in 2008, whose purpose is to search for suitable investment opportunities both in the United States and Internationally. The fund has substantial resources and is looking for opportunities in new start up markets in a wide variety of industries as well as the more mature corporate markets. Our goal is to invest in companies that will not only provide great returns to our investors, improve our clients' profitability, but will also be of great benefit to society at large. For further information on Four Crystal Funding, Inc. please visit our website at: www.fourcrystal.com.
Contact: Mark Cohen
CEO
Cohen Consulting
718-428-7651
E-mail: pnaclgrup@aol.com
FORWARD LOOKING STATEMENT
Statements in this press release other than historical facts are "forward- looking" statements within the meaning of section 27A of the Securities Act of 1933, section 21E of the Securities Exchange Act of 1934. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results. Future operating results of the Company are impossible to predict and no representation, guaranty or warranty is to be inferred from those forward-looking statements. Readers are advised to review the "forward- looking" statements' included in our reports which are filed with the Securities and Exchange Commission .
SOURCE Four Crystal Funding, Inc.
FOHE 1.45 now. Wish I held on this incredibly slow day
FOHE in @ 1.08 out @ 1.25. Not much else moving on my end
WTWO (.06) W2 Energy Inc. to Pursue Biodiesel Market
Wednesday, June 18 2008 10:28 AM, EST
Market Wire "US Press Releases "
NEW YORK, NY -- (MARKET WIRE) -- 06/18/08 -- W2 Energy Inc. (PINKSHEETS: WTWO) ( FRANKFURT : WJD), a waste-to-energy and renewable energy company, is pleased to announce its entry into the biodiesel market.
W2 Energy builds waste-to-energy plants which convert municipal solid waste, tires, agricultural waste, human waste and coal into electricity and syndiesel.
"We can take our syndiesel, mix it with biodiesel, and make high quality diesel with excellent lubricity and temperature specifications," says Mike McLaren, CEO of W2 Energy. "We can also produce methanol with our waste-to-energy plants. The cost of methanol keeps going up. We can make our own methanol for biodiesel production and make biodiesel less expensively than the competition."
For its biodiesel operations, W2 will not use food as feed products or feedstock.
"We will use jatropha, other non-food vegetable oils and waste vegetable oils," says Mike McLaren. "W2 will not make fuel out of food. It's our policy."
W2 Energy's new fuel blend of syndiesel and biodiesel will have specifications equal to or better than today's B20 using petroleum products.
W2 Energy seeks joint venture partners with and without existing biofuels production capabilities. W2 also seeks producers of Jatropha, Algae and Waste vegetable oils who can commit to long term contracts.
"We believe we have great technology and a marketplace hungry for an all renewable, non-food, diesel product. Now we are looking for the right companies to share our vision," added Mike McLaren.
According to the Commission of the European Communities , the EU consumed approximately 874 million gallons of biodiesel in 2005 (a 1.6% share of the EU diesel market), 1.6 billion gallons in 2006 (2.6% of the market), and according to the USDA, is projected to consume 3.0 billion gallons (3.0% of the market) in 2008.
About W2 Energy Inc.
W2 Energy Inc. is a growing, publicly traded company that develops renewable energy technologies and applies it to new generation power systems. Specifically, W2 Energy Inc.'s plasma assisted biomass to energy plants utilize state of the art technologies to produce green energy both fuel (sulfur free diesel) and electricity at the most efficient cost in capital investment and production per/barrel, per/Megawatt.
Safe Harbor for Forward-Looking Statements: Except for historical information contained herein, statements are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the company's actual results in the future periods to differ materially from forecasted projections. These risks and uncertainties include, among other things, energy market volatility, product demand, market competition, and risk inherent to the company's research and development operations.
For further information, please contact:
W2 Energy Inc.
Info@w2energy.com
www.w2energy.com
FOHE 1.05 -34.38% PROMO?
I was thinking the same
ALHI .03 -70.00%
SYMW chart looks good for bounce
DLKM coming back down
DLKM .57 X .60 nice bounce man. Too bad I didn't get a fill
SWVC (.0013) Sackets Harbor Brewing Company Continues Success in Syracuse Market
Wednesday, June 18 2008 9:47 AM, EST
Business Wire "US Press Releases "
SACKETS HARBOR, N.Y.--(BUSINESS WIRE)--
Seaway Valley Capital Corporation (OTC Bulletin Board: SWVC) today reported that its War of 1812 Amber Ale, which is produced by wholly owned subsidiary Sackets Harbor Brewing Company , has been recognized by Syracuse's famous Dinosaur Bar-B-Q (the "Dinosaur") as one of its strongest selling beers on draught. The Dinosaur (www.dinosaurbarbque.com), which is located at 246 Willow St. in Syracuse and has locations in Rochester and New York City , was started in Syracuse in 1983 by three bikers, "bound together by the love of good food, a 55 gallon drum cut in half, and a serious case of wanderlust" and over the years expanded its space to include a full bar and waitress service in a live blues music backdrop. Over the last decade the Dinosaur has been nationally acclaimed as one of the country's best blues clubs and has award winning barbeque cuisine. The Dinosaur also produces and distributes five of its own specialty cooking sauces throughout the U.S., England and Australia .
Paul Massena, Beverage Manager at the Syracuse Dinosaur, stated, "The 1812 Amber Ale is one of the strongest sellers due to its local identity and its natural pairing to Bar-B-Q cuisine. It's a perfect match." Tracey Pastella, Day Managing Bartender, stated that "1812 Amber Ale is hands down the most frequently requested ale on tap." Due to the continuing success of Sackets Harbor 1812 Amber Ale on tap, Paul Massena is also putting it in the Dinosaur's popular seasonal exterior bar.
Sackets Harbor Brewing Company premium beers are sold in Syracuse by TJ Sheehan Distributing Incorporated .
About Sackets Harbor Brewing Company
Sackets Harbor Brewing Company develops, produces, and markets micro brewed beers such as the award winning "1812 Amber Ale" and "Railroad Red Ale" as well as "Thousand Island Pale Ale", "1812 Amber Ale Light" and "Independence Wheat" specialty beers. Its "1812 Amber Ale" is the company's flagship brand and was the winner of a Silver Award at the 1998 World Beer Championship. The company has also developed complementary products such Sackets Harbor Coffee and Sackets Harbor Brewing Co. Root Beer.
About Seaway Valley Capital Corporation
Seaway Valley Capital Corporation makes equity, equity-related, and debt investments in companies that require expansion capital. Seaway also seeks investments in leveraged buyouts and restructurings. Seaway will consider investment opportunities in a number of different industries, including retail, restaurants, media, business services, manufacturing, and select technologies.
Safe Harbor Statement
This press release contains statements that may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of the Company, and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Source: Seaway Valley Capital Corporation
DLKM got no fill @ .4001
DLKM .50 -39.02%
Exactly. I was trying the 90 puts but the spread is huge and theres no selling on the bid.
Yea, mine were delayed too. Trying to decide what I'm going to do now...
HJHO (.50) Halcyon Jets Releases Podcast Interview with CEO Mitchell Blatt and A-List Jets President Gordon Bijelonic
Wednesday, June 18 2008 9:30 AM, EST
Business Wire "US Press Releases "
NEW YORK --(BUSINESS WIRE)--
Halcyon Jets Holdings, Inc. (OTCBB:HJHO), pioneering elite concierge services for the private air travel services industry, announces the online availability of an extensive interview podcast from fee-based SmallcapInsights with Halcyon Jets CEO Mitchell Blatt and A-List Jets Founder and President Gordon Bijelonic.
The interview details Halcyon's recently announced intention to acquire a majority interest in Maryland -based A-List Jets as part of an aggressive roll-up strategy. As the first acquisition by Halcyon, the integration of A-List Jets would significantly add capacity to existing markets and bring a strong international presence to the company. Mr. Blatt and Mr. Bijelonic also share their views on the compelling potential for this growth-driven business and how Halcyon is in a unique position to capitalize on the exceptional growth of the private concierge air travel sector.
"The commercial airline industry provides us with the opportunity for growth," said Mr. Blatt, Chief Executive Officer of Halcyon Jets Holdings . "The longer lines, greater security, long delays, all of that has fed into the private jet industry. Our level of customer requires that extra bit of service and we provide it. Halcyon has had consistent growth since inception."
To listen to the entire podcast and to subscribe to SmallcapInsights, please visit http://www.trilogy-capital.com/podcast.html
About Halcyon Jets Holdings, Inc.
Halcyon Jets Holdings, Inc. ("Halcyon Jets" or "the Company"), operating through its wholly owned subsidiary Halcyon Jets Inc. , is a world-class broker of on-demand aircraft services, serving as agent of its customers in arranging for their transportation needs. Halcyon Jets capitalizes on the highest-margin segment of the aviation industry: elite business and luxury travelers who demand the highest levels of service, professionalism and comfort. The Company is committed to building revenues and shareholder value through organic growth as well as possible acquisitions. To serve this growing market, Halcyon has developed a luxury service unique in its ability to create a comprehensive White Glove-Red Carpet travel experience. Halcyon Jets takes pride in having the most flexible card program in the industry, with the lowest cost of entry, as well as the highest level of service. Halcyon Jets has access to a fleet of aircraft reaching thousands of airports, large and small, nationally and internationally. Halcyon Jets does not own or operate the aircraft on which our customer's fly but through business partnerships with the aircraft operators, Halcyon is able to focus exclusively on providing the industry's most exemplary service. All Halcyon-arranged flights are operated by Federal Aviation Administration certificated Part 135 air carriers that have the highest independently determined safety ratings.
For more information, please visit http://www.halcyonjets.com.
For investor-specific information and resources, visit http://www.trilogy-capital.com/tcp/hjho.
To view current stock quotes and news, visit
http://www.trilogy-capital.com/tcp/hjho/quote.html.
To read the Company's Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/hjho/factsheet.html.
Safe Harbor for Forward-Looking and Cautionary Statements
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, government regulation, market demand and other factors disclosed in Halcyon's Form 8-K filed with the Securities and Exchange Commission on August 23, 2007 .
Source: Halcyon Jets Holdings, Inc.
Looks like a plan. I was thinking of buying puts @ open then buying calls on reversal
Nasty selloff. Hopefully the options are volitile
ORGC (.85) Organic Alliance Board Member Named Chairman of China's Fourth-Largest Hypermarket Chain
Wednesday, June 18 2008 9:15 AM, EST
PR Newswire "US Press Releases "
SAN ANTONIO, Texas , June 18 /PRNewswire-FirstCall/ -- Today, Organic Alliance, Inc. (Pink Sheets: ORGC) is pleased to announce that Jim Haworth, company board member and Director, has been promoted to Chairman of Lotus Supercenters, who through its subsidiaries are engaged in the operation of large scale one-stop shopping centers, mainly located in the north and south of China .
Lotus Supercenters provide customers with an extensive grocery selection including fresh produce, along with clothing and household items, enabling true one-stop shopping for its customers. Hypermarkets have been the fastest growing retail channel in mainland China , and are expected to grow at an annual rate of 12% during 2005-2010, outpacing average retail growth sales of 6%.
"We are excited for Jim and congratulate our colleague on this outstanding achievement," said Tom Morrison, Organic Alliance CEO. "We are very fortunate to be able to leverage Jim's extensive experience, expertise, and vast network in the food industry to help accelerate our company's growth. His industry insight and relationships are key enablers of our business plan," said Morrison.
Mr. Haworth will remain as board member and Director for Organic Alliance.
About Organic Alliance
Organic Alliance intends to become one of the world's leading providers of USDA certified organic crops to many of the country's leading consumer package goods manufacturers, food processors, grocery, and retail restaurant chains. Organic Alliance sources top quality, safe tested and certified organic at the source -- prior to customer shipment utilizing USDA certification in conjunction with the in-house OAI Quality Team. Company CEO Tom Morrison was CEO of Superior Farming, formerly one of the largest corporate farms and organic farming operations in the world before being acquired by Sun World International and later Black Diamond Capital Management. Organic Alliance plans to open its Bakersfield, CA sales and marketing office in August, 2008.
For more information, please visit http://organicallianceinc.com/ or contact: Sarahjane G. Reil at 210.826.8900
'Safe Harbor' Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements which address actual results could differ materially from those expressed or implied in forward-looking statements. These statements are made on the basis of management's views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as management 'believes,' 'expects,' 'anticipates,' 'foresees,' 'forecasts,' 'estimates' or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
SOURCE Organic Alliance, Inc.
HCPC (.0002) Heritage Capital Credit Corporation Provides Corporate Update
Wednesday, June 18 2008 9:15 AM, EST
PR Newswire "US Press Releases "
WILMINGTON, Del ., June 18 /PRNewswire-FirstCall/ -- Heritage Capital Credit Corporation (Pink Sheets: HCPC) provides the following update on the current activities of the Company.
-- The Company has signed up for the OTC Market Report that provides market data enabling management, board members and shareholders to view the "HCPC" stock performance. The reports will be posted regularly on the website: http://www.heritagecapitalcreditcorp.com.
-- The Company's subsidiary, Independent Capital Credit Corporation , has updated its list of projects in the pipeline. For more information, visit http://www.independentcapitalcreditcorp.com.
-- The Certified Public Accountants are continuing the process of completing the financial audits for 2005, 2006 and 2007 and a review of the first quarter ending March 31, 2008 . The financial results for the first quarter ended March 31, 2008 are expected to be released as soon as possible.
About Heritage Capital Credit Corporation
The Heritage business model, which is implemented through its subsidiary, Independent Capital Credit Corporation , is to arrange financing for real property and commercial revenue producing assets.
Safe Harbor
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking information made on the company's behalf. All statements, other than statements of historical facts which address the company's expectations of sources of capital or which express the company's expectation for the future with respect to financial performance or operating strategies, can be identified as forward-looking statements. Such statements made by the company are based on knowledge of the environment in which it operates, but because of the factors previously listed, as well as other factors beyond the control of the company, which include the ability of the company to implement its business plans and the ability of the auditor to finalize the financial audit, actual results may differ materially from the expectations expressed in the forward-looking statements.
Contact: Heritage Capital Credit Corporation
Richard Razzeca, VP Investor Relations
302-778-4222
info@heritagecapitalcreditcorp.com
SOURCE Heritage Capital Credit Corporation